癌症免疫治疗学会(SITC)关于急性白血病免疫治疗的临床实践指南,2.0 版
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.
急性白血病是一种影响所有年龄段的血液系统恶性肿瘤。
DISEASE HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.
急性白血病是一种影响所有年龄段的血液系统恶性肿瘤。
Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.
我们的发现为在CD1d表达的血液系统恶性肿瘤患者中探索CD1d-Vδ2 bsTCE与IMiD来那度胺的联合治疗提供了依据。
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia
22例AML(n=13)和T-ALL(n=9)患者入组,中位年龄63岁(范围31-77)。
Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer.
T细胞导向的免疫疗法已改变了血液系统恶性肿瘤的治疗,但持久获益仍受限于复发、持续性差、免疫重建不完全和感染。
Plasticity under pressure: biology and detection of lineage switch in acute leukemia.
复发性急性白血病可能难以挽救。
Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution.
近年来,嵌合抗原受体(CAR)技术的发展极大推动了细胞免疫治疗的进步。
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia.
这些发现支持BCMA作为AML中一种新型免疫治疗靶点。
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.
西达基奥仑赛(cilta-cel)和艾基奥仑赛(ide-cel)这两种靶向B细胞成熟抗原(BCMA)的CAR-T 细胞疗法,已经改变了复发/难治性多发性骨髓瘤的治疗结局;
TIM-3 in AML: a janus-faced orchestrator of immune exhaustion and leukemic self-renewal.
急性髓系白血病(AML)由于耐药白血病干细胞(LSCs)驱动的复发以及深度免疫抑制的微环境,仍是一项治疗挑战。
A Bispecific Anti-Fluorescein × Anti-CD3 T-cell Engager in Combination with Fluoresceinated Adaptors Enables Lysis of AML Cells.
这些数据共同表明,AdFITC-TCE 与任意给定的荧光素化结合物联用,可能是一种激活 T 细胞的多功能工具,从而引起相应靶细胞的裂解。
MEMBER ACCOUNT
登录成功会直接打开下一页。